Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Completed · Phase 1
Conditions studied: Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
In brief
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Key facts
- Study ID
- NCT02655822
- Run by
- Corvus Pharmaceuticals, Inc.
- People needed
- 502
- Starts
- 2016-01-01
- Expected to finish
- 2021-07-01
- Last updated by the study team
- 2021-08-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arizona Cancer Center — Tucson, Arizona, United States
- University of California - San Francisco — San Francisco, California, United States
- Stanford Cancer Institute — Stanford, California, United States
- Yale University — New Haven, Connecticut, United States
- University of Miami Hospital and Clinics — Miami, Florida, United States
- Rush University Medical Center — Chicago, Illinois, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- University of Pittsburgh Medical Center Cancer Center — Pittsburgh, Pennsylvania, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Royal Brisbane and Women's Hospital — Brisbane, Queensland, Australia
- Monash Health — Clayton, Victoria, Australia
- Cross Cancer Institute — Edmonton, Alberta, Canada
- British Columbia Cancer Agency - Vancouver Centre — Vancouver, British Columbia, Canada
- The Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.